CHARLES LEROY STEINBERG, B.S., M.D., F.A.C.P.; ANDRIES I. ROODENBURG, M.D., M.S. (Medicine)
Disappointment in the long-term treatment of rheumatic diseases with cortisone and allied steroids has stimulated a search for newer compounds. Two of these compounds are metacortandracin and metacortandralone, which were recently reported as being of value in the treatment of rheumatoid arthritis by Bunim et al.1 They recently made preliminary observations on the antirheumatic and anti-inflammatory potency of these synthetic steroids. The structural formula of metacortandracin and metacortandralone and their close relationship to cortisone and hydrocortisone are noted in the figures below. Studies2 indicated that these compounds possessed three times the activity of cortisone and twice the activity of hydrocortisone,
STEINBERG CL, ROODENBURG AI. METACORTANDRACIN (METICORTEN) IN THE TREATMENT OF DISSEMINATED LUPUS ERYTHEMATOSUS AND PERIARTERITIS NODOSA*. Ann Intern Med. 1956;44:316–336. doi: https://doi.org/10.7326/0003-4819-44-2-316
Download citation file:
Published: Ann Intern Med. 1956;44(2):316-336.
Lupus Erythematosus, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use